$18.72

+0.43 (+2.35%)

Weekly Expected Move ±4.1%

$17 $17 $18 $19 $19

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Buy · Power 63 · $21.5B mcap · 1.14B float · 0.830% daily turnover · Short 44% of daily vol

Credit Risk of going bust: lower than 54% of companies Debt: 39.3% of company value Bonds: $302.8M held by 306 funds, 161 bp over Treasuries → details ▾

Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.76 (down 96%), Viatris Inc. would be worth roughly what it owes.
Total debt $13.63B against a stock market value of $21.01B.
Distance to default 5.55 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $7.55B (short-term plus half of long-term), stock volatility 32.3%; Altman Z 1.13. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$14.3B -3.0% ▼

5Y CAGR: +3.7%

Gross Profit

$5.0B -10.8% ▼

5Y CAGR: +5.7%

Operating Income

-$2.7B -26467.3% ▼

Net Income

-$3.5B -454.2% ▼

EPS (Diluted)

$-3.00 -466.0% ▼

EBITDA

-$395M -114.0% ▼

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$17.9B	$16.3B	$15.4B	$14.7B	$14.3B
YoY Growth	+49.7%	-9.1%	-5.1%	-4.5%	-3.0%
Cost of Revenue	$12.3B	$9.8B	$9.0B	$9.1B	$9.3B
Gross Profit	$5.6B	$6.5B	$6.4B	$5.6B	$5.0B
Gross Margin	31.2%	40.0%	41.7%	38.2%	35.1%
R&D Expenses	$681M	$662M	$805M	$809M	$966M
SG&A Expenses	$4.5B	$4.2B	$4.7B	$4.4B	$3.8B
Operating Expenses	$5.6B	$4.9B	$5.7B	$5.6B	$7.7B
Operating Income	-$34M	$1.6B	$766M	$10M	-$2.7B
Operating Margin	-0.2%	9.9%	5.0%	0.1%	-18.6%
Interest Expense	$636M	$592M	$573M	$550M	$471M
Income Before Tax	-$664M	$2.8B	$203M	-$623M	-$3.7B
Tax Expense	$605M	$735M	$148M	$11M	-$150M
Net Income	-$1.3B	$2.1B	$55M	-$634M	-$3.5B
Net Margin	-7.1%	12.8%	0.4%	-4.3%	-24.6%
EPS (Diluted)	$-1.05	$1.71	$0.05	$-0.53	$-3.00
EBITDA	$4.5B	$6.4B	$3.5B	$2.8B	-$395M
Shares Outstanding	1.21B	1.22B	1.21B	1.19B	1.17B

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$3.8B	$3.5B	$3.3B	$3.6B	$3.8B	$3.7B	$3.5B	$3.8B
Cost of Revenue	$2.3B	$2.3B	$2.1B	$2.2B	$2.4B	$2.6B	$2.4B	$2.3B
Gross Profit	$1.5B	$1.2B	$1.2B	$1.3B	$1.4B	$1.1B	$1.2B	$1.5B
Gross Margin	38.9%	34.4%	35.7%	37.2%	36.8%	30.6%	32.9%	38.8%
R&D Expenses	$198M	$206M	$222M	$219M	$250M	$275M	$249M	$248M
SG&A Expenses	$1.0B	$1.0B	$948M	$929M	$883M	$1.0B	$929M	$1.1B
Operating Expenses	$1.2B	$1.4B	$4.0B	$1.1B	$1.1B	$1.4B	$1.2B	$1.5B
Operating Income	$226M	-$180M	-$2.9B	$233M	$252M	-$266M	-$80M	$6M
Operating Margin	6.0%	-5.1%	-88.6%	6.5%	6.7%	-7.2%	-2.3%	0.2%
Interest Expense	$146M	$120M	$116M	$117M	$120M	$120M	$120M	$121M
Income Before Tax	$90M	-$526M	-$3.1B	-$217M	-$8M	-$343M	-$247M	-$64M
Tax Expense	-$4M	-$10M	-$55M	-$212M	$120M	-$3M	-$424M	$55M
Net Income	$95M	-$516M	-$3.0B	-$5M	-$128M	-$340M	$176M	-$119M
Net Margin	2.5%	-14.6%	-93.5%	-0.1%	-3.4%	-9.2%	5.0%	-3.2%
EPS (Diluted)	$0.08	$-0.43	$-2.55	$-0.00	$-0.11	$-0.30	$0.15	$-0.10
EBITDA	$906M	$340M	-$2.3B	$578M	$800M	$543M	$644M	$729M
Shares Outstanding	1.20B	1.19B	1.19B	1.17B	1.16B	1.15B	1.18B	1.16B

VTRS NASDAQ